In contrast, this intervention was effective as a therapeutic strategy in the presence of steatosis, since, in the BD+IL-10+LT treatment group, we observed reduced transaminase levels, damage scores, ALP, total levels of bilirubin, vWF, HA, MPO, edema, and MDA in grafts in the presence of steatosis with respect to the results of the BD+LT group (Figures 4, 5). This evidence concerns the gene IL10 and steatosis.